S100 Protein, beta-beta homodimer, Human Brain (S100b)

Although histochemical staining of the S100 protein family has been used for many years in the diagnosis of malignant melanoma, recent studies suggest one of the proteins comprising the S100 family, S100b, has particular utility in many aspects of the clinical management of malignant melanoma. This protein has been shown to be of use in staging malignant melanoma, in establishing prognosis, in evaluating treatment success and in predicting relapse. S100b is an independent prognostic factor and pretreatment circulating S100B concentrations predict duration of survival in melanoma patients. Survival is significantly longer in melanoma patients with normal S100b levels compared to those with elevated levels.\n\nApplications: \nSuitable for use as a standard in immunoassays, as an immunogen for antiserum production and tracer for iodination. Other applications not tested.\n\nRecommended Dilution:\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nStore lyophilized product at -20 degrees C. After reconstitution, aliquot and store at -20 degrees C. Avoid multiple freeze/thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S0052-18B

Size

1mg

Applications

ELISA

Reactivities

Hum

Form

Supplied as a purified, lyophilized powder. Lyophilized from deionized water containing 5mM EDTA and 5mM 2-mercaptoethanol. Reconstitute in 5mM 2-mercaptoethanol solution. No preservative added.

Purity

(same/more than) 95%

References

1. Influence of pericardial suction blood retransfusion on memory function and release of protein S100B. Svenmarker S, Engstrom KG, Jansson E, Perfusion 2004 Nov;19(6):337-43 2. S100B and NSE serum levels in patients with Parkinson's disease. Schaf DV, Tort AB, Schestatsky P, Parkinsonism Relat Disord 2005 Jan;11(1):39-43 3. Controversial significance of early S100B levels after cardiac surgery. Jonsson H, Johnsson P, Alling C, BMC Neurol 2004 Dec 16;4(1):24 4. Redox modifications of the C-terminal cysteine residue cause structural changes in S100A1 and S100B proteins. Zhukova L, Zhukov I, Wyslouch-Cieszynska A, Biochim Biophys Acta 2004 Dec 6;1742(1-3):191-201 5. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Adami C, Bianchi R, Donato R, Biochim Biophys Acta 2004 Dec 6;1742(1-3):169-77 6. S100B protein is released by in vitro trauma and reduces delayed neuronal injury. Willoughby KA, Kleindienst A, Chen T, J Neurochem 2004 Dec;91(6):1284-91.